About ABL Bio
ABL Bio is biotech research company focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
1. Lead Molecule (ABL001): Bispecific antibody targeting VEGF and Dll4 (Phase 1, Q4, 2017)
2. ADC (Antibody Drug Conjugate) projects
3. T cell engaging Bispecific antibody
4. Immunooncology MoAb
5. Immunooncology Bispecific antibody
6. Synuclein targeting antibody with BBB-Crossing Trojan Horse Bispecific Antibody
State of Ownership
Assistant Manager at ABL Bio, Inc., ABL Bio, Inc.
Director of Corporate Development at Neural Analytics, Neural Analytics
Business Development Executive, Nature Publishing Group
CEO & Co-Founder, Zapnito
Business Development Associate Director, University of Michigan
Business Development Executive, Nature Publishing Group, Springer Nature